...that harbor an MLL1 rearrangement. SNDX-5613 is a first-in-class selective inhibitor of Menin-MLL binding interaction. Compugen Ltd....

...antibodies, hired Steve Arkinstall as CEO. He was CEO of Elstar Therapeutics Inc. Immuno-oncology company Compugen Ltd....
...BMS. Elizabeth S. Eaton, Staff Writer Fred Hutchinson Cancer Research Center GlaxoSmithKline plc Provention Bio Inc. Antengene Corp. Ltd. Revitope Oncology Inc. Compugen Ltd. Wellington...

...PVRIG has been limping along with a single program: COM701 (cgen-15029), an anti-PVRIG mAb from Compugen Ltd....

...hired Kirk Christoffersen as its first CBO. He was SVP, corporate and business development at Compugen Ltd....

...Zweifach is co-founder and CEO of Nuvelution Pharma Inc. (Cambridge, Mass.) and board member of Compugen Ltd....

...Compugen will reduce headcount by 35 (35%), with cuts coming primarily from R&D. Compugen Ltd. (NASDAQ:CGEN) said...
...is a mAb targeting poliovirus receptor related immunoglobulin domain containing (PVRIG; CD112R). Shannon Lehnbeuter, Staff Writer COM701, cgen-15029 Compugen Ltd....

...new checkpoint target poliovirus receptor related immunoglobulin domain containing (PVRIG; CD112R) (see "Computing Checkpoints" ). Compugen...
...The partners could explore other combinations through other trials, including BMS-sponsored trials, under the deal. Compugen...
...11. Compugen Ltd. (NASDAQ:CGEN), Holon, Israel Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Business: Cancer Jennie Walters COM701, cgen-15029 Compugen Ltd. Bristol...

...After 25 years as a discovery company, Compugen Ltd. is about to enter the clinic for the...
...could allow COM701 to work where PD-1 inhibitors don’t. COM701 is a mAb against PVRIG. Compugen...
...checkpoint inhibitors in hand, Compugen then set out to elucidate their functions in preclinical studies. Compugen...

...plc (LSE:AZN; NYSE:AZN) an exclusive license to develop multiple bi-specific and multi-specific immuno-oncology antibody products. Compugen...
...up to $200 million in milestones for the first product; if additional products are developed, Compugen...
...is also eligible for royalties. MedImmune will be responsible for research, development and commercial activities. Compugen Ltd....

...Capital, which participated in BeyondSpring's $15.3 million venture round in 2016. Drug target discovery company Compugen Ltd....